• Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.
Dalakas MC, Aksamit AJ, Madden DL, Sever JL. Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis. Arch Neurol. 1986;43(9):933–935. doi:10.1001/archneur.1986.00520090061018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: